iTeos Belgium SA

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.iteostherapeutics.com

Clinical Trials

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Metastatic NSCLC - Non-Small Cell Lung Cancer

Interventions: Drug: inupadenant
Drug: Placebo
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2022-06-03

Last Posted Date: 2024-06-24

Lead Sponsor: iTeos Belgium SA

Target Recruit Count: 186

Registration Number: NCT05403385

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Innovative Clinical Research Institute (ICRI), Whittier, California, United States
🇺🇸
Mid-Florida Hematology & Oncology Centers, PA, Orange City, Florida, United States

and more 64 locations

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: EOS884448
Drug: Iberdomide
Drug: Dexamethasone

First Posted Date: 2022-03-21

Last Posted Date: 2024-10-26

Lead Sponsor: iTeos Belgium SA

Target Recruit Count: 16

Registration Number: NCT05289492

Locations: 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸
Eastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States
🇧🇪
ZNA Cadix, Antwerp, Belgium

and more 10 locations

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Head and Neck Cancer
Advanced Cancer
Lung Cancer
Melanoma

Interventions: Drug: EOS-448
Drug: inupadenant
Drug: pembrolizumab
Drug: Dostarlimab
Drug: SOC chemotherapies

First Posted Date: 2021-09-29

Last Posted Date: 2024-06-21

Lead Sponsor: iTeos Belgium SA

Target Recruit Count: 153

Registration Number: NCT05060432

Locations: 🇧🇪
Cliniques universitaires St Luc-UCL, Brussels, Belgium
🇧🇪
Jessa Ziekenhuis, Hasselt, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium

and more 39 locations

First-In-Human Study of EOS884448 in Participants With Advanced Cancers.

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: EOS884448

First Posted Date: 2020-04-06

Last Posted Date: 2022-06-16

Lead Sponsor: iTeos Belgium SA

Target Recruit Count: 40

Registration Number: NCT04335253

Locations: 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇧🇪
Cliniques universitaires St Luc-UCL, Brussels, Belgium
🇧🇪
GZA Ziekenhuizen campus Sint-Augustinus, Antwerp, Belgium

and more 1 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy